{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:04:07Z","timestamp":1770959047297,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,12]]},"DOI":"10.7759\/cureus.103507","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:15:12Z","timestamp":1770956112000},"source":"Crossref","is-referenced-by-count":0,"title":["Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors on Atherosclerotic Cardiovascular Risk Among Patients With Type 2 Diabetes in Primary Health Care Settings in Jeddah, Saudi Arabia"],"prefix":"10.7759","author":[{"given":"Rahaf","family":"A\u200eljohani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyam","family":"Aldubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inas","family":"Bagabas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia","family":"Al-Ghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohoud","family":"Balkhair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujainah","family":"Basubrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama","family":"Rammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399816999201012200841","article-title":"Current status of knowledge and awareness of diabetes mellitus in Saudi Arabia","volume":"17","author":"Robert AA","year":"2021","unstructured":"Robert AA, Al Awad AD, Al Dawish MA. Current status of knowledge and awareness of diabetes mellitus in Saudi Arabia. Curr Diabetes Rev. 2021, 17:e101220186818. 10.2174\/1573399816999201012200841","journal-title":"Curr Diabetes Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2021.42.5.20200676","article-title":"Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council countries","volume":"42","author":"Aljulifi MZ","year":"2021","unstructured":"Aljulifi MZ. Prevalence and reasons of increased type 2 diabetes in Gulf Cooperation Council countries. Saudi Med J. 2021, 42:481-90. 10.15537\/smj.2021.42.5.20200676","journal-title":"Saudi Med J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, et al.. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021, 9:22-31. 10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.532719","article-title":"Prevalence of cardiovascular disease and associated factors among type 2 diabetes patients in selected hospitals of Harari region, Eastern Ethiopia","volume":"8","author":"Regassa LD","year":"2020","unstructured":"Regassa LD, Tola A, Ayele Y. Prevalence of cardiovascular disease and associated factors among type 2 diabetes patients in selected hospitals of Harari region, Eastern Ethiopia. Front Public Health. 2020, 8:532719. 10.3389\/fpubh.2020.532719","journal-title":"Front Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29489","article-title":"Prevalence of cardiovascular risk factors among patients with diabetes mellitus type 2 at King Fahad University Hospital, Saudi Arabia","volume":"14","author":"Jatoi NA","year":"2022","unstructured":"Jatoi NA, Elamin YA, Said AH, Al-Namer B, Al-Muallim FA, Al-Nemer FF, Al-Halal FM. Prevalence of cardiovascular risk factors among patients with diabetes mellitus type 2 at King Fahad University Hospital, Saudi Arabia. Cureus. 2022, 14:e29489. 10.7759\/cureus.29489","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson TR","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018, 17:83. 10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S190356","article-title":"Cardiovascular risk reduction in type 2 diabetes: therapeutic potential of dapagliflozin","volume":"12","author":"Avgerinos I","year":"2019","unstructured":"Avgerinos I, Liakos A, Tsapas A, Bekiari E. Cardiovascular risk reduction in type 2 diabetes: therapeutic potential of dapagliflozin. Diabetes Metab Syndr Obes. 2019, 12:2549-57. 10.2147\/DMSO.S190356","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan MS","year":"2020","unstructured":"Khan MS, Fonarow GC, McGuire DK, et al.. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation. 2020, 142:1205-18. 10.1161\/CIRCULATIONAHA.120.045888","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HJ, Cuthbertson DJ, Wilding JP. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 398:262-76. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01400-9","article-title":"GLP-1 receptor agonists vs. SGLT-2 inhibitors:\u00a0the gap seems to be leveling off","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K. GLP-1 receptor agonists vs. SGLT-2 inhibitors:\u00a0the gap seems to be leveling off. Cardiovasc Diabetol. 2021, 20:205. 10.1186\/s12933-021-01400-9","journal-title":"Cardiovasc Diabetol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108681","article-title":"Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: a 24\u00a0months follow-up study","volume":"173","author":"D'Onofrio L","year":"2021","unstructured":"D'Onofrio L, Mignogna C, Carlone A, et al.. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: a 24\u00a0months follow-up study. Diabetes Res Clin Pract. 2021, 173:108681. 10.1016\/j.diabres.2021.108681","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455626-effect-of-glucagon-like-peptide-1-glp-1-receptor-agonists-and-sodium-glucose-cotransporter-2-sglt-2-inhibitors-on-atherosclerotic-cardiovascular-risk-among-patients-with-type-2-diabetes-in-primary-health-care-settings-in-jeddah-saudi-arabia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:15:13Z","timestamp":1770956113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455626-effect-of-glucagon-like-peptide-1-glp-1-receptor-agonists-and-sodium-glucose-cotransporter-2-sglt-2-inhibitors-on-atherosclerotic-cardiovascular-risk-among-patients-with-type-2-diabetes-in-primary-health-care-settings-in-jeddah-saudi-arabia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.103507","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}